Individualized TCM Pattern-Based Thread-Embedding Acupuncture Plus Auricular Acupressure for Chronic Insomnia

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-75
SponsorUniversity of Medicine and Pharmacy at Ho Chi Minh City

About this trial

Chronic insomnia disorder is a common sleep disorder associated with impaired daytime functioning and may be accompanied by alterations in immune-inflammatory and gut-related biological processes. Traditional Chinese medicine (TCM) uses pattern differentiation to individualize treatment; however, the additional clinical value of pattern-based treatment compared with a standardized protocol remains insufficiently established.

This randomized controlled trial will evaluate whether individualized TCM pattern-based thread-embedding acupuncture combined with auricular acupressure improves sleep quality more effectively than the same therapeutic modalities delivered using a standardized fixed-point protocol in adults with chronic insomnia disorder.

Participants will be classified as having either Heart-Spleen Deficiency or Liver Qi Stagnation with Spleen Deficiency according to prespecified TCM diagnostic criteria and randomized 1:1 to individualized pattern-based treatment or standardized treatment.

The primary outcome is the change in Pittsburgh Sleep Quality Index (PSQI) score from baseline to the end of treatment. Secondary clinical outcomes include insomnia severity measured by the Insomnia Severity Index (ISI), gastrointestinal symptoms measured by the Gastrointestinal Symptom Rating Scale (GSRS), and adverse events.

Serum interleukin-6 (IL-6) and fecal calprotectin will be assessed as exploratory systemic and gut-related inflammatory biomarkers. These biomarkers are intended to explore biological correlates potentially relevant to gut-brain interactions and are not considered diagnostic markers of insomnia or direct measures of the microbiota-gut-brain axis.

Clinical outcomes will additionally be assessed at Week 10, four weeks after completion of scheduled treatment, to evaluate persistence of clinical effects.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • Thread embedding acupuncture

    Other intervention

    Thread embedding acupuncture is performed twice at a 4-week interval using the points HT7 (Shenmen), PC6 (Neiguan), SP6 (Sanyinjiao), GB20 (Fengchi), and Anmian.

  • Auricular acupressure

    Other intervention

    Auricular acupressure using Vaccaria seeds is applied and replaced every 2 weeks on the points Shenmen (TF4), Subcortex, Occiput, Forehead, Kidney, and Endocrine. Participants are instructed to perform self-massage on the ear seeds 3-5 times daily for 1-2 minutes per point, particularly 30 minutes before bedtime.

  • Thread embedding acupuncture

    Other intervention

    Thread embedding acupuncture is performed twice at a 4-week interval using absorbable sutures. The selection of acupoints is strictly tailored to the participant's Traditional Chinese Medicine (TCM) syndrome differentiation: Heart-Spleen Deficiency: The procedure utilizes the points BL15 (Xinshu), BL20 (Pishu), ST36 (Zusanli), SP6 (Sanyinjiao), and ST25 (Tianshu). Liver Qi Stagnation with Spleen Deficiency: The procedure utilizes the points BL18 (Ganshu), LR3 (Taichong), GB34 (Yanglingquan), SP6 (Sanyinjiao), and PC6 (Neiguan).

  • Auricular acupressure

    Other intervention

    Auricular acupressure using Vaccaria seeds (ear seeds) is applied to reflex points on the ear and replaced every 2 weeks throughout the 8-week study period. The selection of ear points is customized based on the TCM syndrome. Heart-Spleen Deficiency: The points include Heart (CO15), Spleen (CO13), Stomach (CO4), TF4 (Shenmen), and Subcortex (AT4). Liver Qi Stagnation: The points include Liver (CO12), Gallbladder (CO11), Sympathetic (AH6a), TF4 (Shenmen), and Subcortex (AT4). Participants are instructed to perform self-massage on the ear seeds for 1-2 minutes per point, 3-5 times daily, particularly 30 minutes before bedtime.

Treatment groups

70 Participants
are divided into 2 treatment groups
Group A: Standardized Fixed-Point ProtocolActive comparator 2 interventions
Group B: Individualized TCM Pattern-Based ProtocolExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Change in Pittsburgh Sleep Quality Index (PSQI) Global Score From Baseline to End of Treatment

The Pittsburgh Sleep Quality Index consists of 19 self-rated items grouped into seven components. Each component is scored from 0 to 3, producing a global score ranging from 0 to 21. Higher scores indicate poorer sleep quality. The primary treatment effect will be evaluated as the between-group difference in change in PSQI global score from baseline to the prespecified end-of-treatment assessment.

Time frame
Baseline to Week 6 (End of Treatment)

Secondary outcomes

1

Change in Insomnia Severity Index (ISI) Score

The Insomnia Severity Index is a 7-item questionnaire assessing the severity and impact of insomnia symptoms. Total scores range from 0 to 28, with higher scores indicating greater insomnia severity.

Time frame
Baseline to Week 6 (End of Treatment)
2

Change in Fecal Calprotectin

Fecal calprotectin will be measured as an exploratory biomarker of gut-related inflammatory activity. Changes will be compared between randomized treatment groups. Fecal calprotectin will not be interpreted as a direct measure of gut microbiota composition or as proof of a microbiota-gut-brain axis mechanism.

Time frame
From baseline to week 6 (End of Treatment)
3

Change in Serum Interleukin-6 (IL-6)

Serum IL-6 will be measured as an exploratory biomarker of systemic inflammatory activity. Changes will be compared between randomized treatment groups. IL-6 is not considered a diagnostic biomarker of insomnia in this study.

Time frame
From baseline to week 6 (End of Treatment)
4

Change in PSQI Global Score During Treatment and Follow-up

PSQI global scores will also be assessed at intermediate and post-treatment follow-up visits to characterize the trajectory and persistence of treatment effects.

Time frame
Baseline, Week 4, Week 6, and Week 10 (4-week post-intervention follow-up)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.